SBIR/STTR Research Award

In vitro substrate assay for multi-drug resistance

Award identifier c66b4ea88c4ab8602d522974c6f735e2e61ed8bf1932244aebea0c708b01ac7cAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$140,384

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
GLSynthesis Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): One criterion of a successful drug is its ability to reach its target site. A major reason that candidates are ineffective is that the compounds do not enter cells or cross the barriers that exist between the various compartments of the body, e.g. intestinal epithelium, blood-brain barrier, placenta. In addition to the passive barrier of the cell membrane, many membranes contain energy (ATP) driven efflux proteins, "multi-drug resistance proteins" (MDRP), which actively pump many drugs away from their target tissue. In this project, we propose to develop an innovative, simple and effective assay to determine the susceptibility of drug candidates to a major member of the MDRP family, p-glycoprotein (pgp). This unique assay should provide a valuable tool in drug discovery. The development of this assay for one MDRP will also provide the groundwork for future assays for other members of the MDRP families. What we propose to develop is a new form of Fluorosome, Fluorosome-frans-pgp, based in part on GLSynthesis' existing Fluorosome Technology. Specifically, we propose to clone and express human pgp and incorporate it into the membrane bilayer of Fluorosome-frans. Fluorosome-trans are liposomal nano-particles developed by GLSynthesis to measure the passive permeabilities of drugs through membrane bilayers. Functional incorporation of pgp into Fluorosome-frans-pgp will be confirmed by measuring ATPase activity and ATPdependent flux of test substrates. Predictions of kinetic and equilibrium results for substrate-dependent transport will be verified by experiments with test compounds. Protocols for the testing of potential substrates will be established, and data for ATP-dependent transport of a series of known pgp substrates will be acquired. Fluorosome-frans-pgp will provide a convenient in vitro assay for determining the susceptibility of drug candidates to exclusion by pgp, a major member of the multi-drug resistance protein family. The Fluorosome-f/-ans-pgp assay will be applicable to a wide range of compounds, simple in execution and costeffective, and will require only standard fluorescence spectrophotometers. The Fluorosome-frans-pgp assay is adaptable to multiwell plate formats and robotics, for eventual moderate to high throughput screening of drug candidate libraries.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.